[Clinical evaluation of panipenem/betamipron in children].
Panipenem/betamipron (PAPM/BP), a new injectable carbapenem antibiotic, was evaluated for its safety and efficacy in children. Ninety three percentage (14 in 15 cases) of various infections were cured with PAPM/BP therapy. Transient skin rash occurred in 1 case, probably due to the histamine-like effect of PAPM/BP. The plasma half life of panipenem was 0.85 +/- 0.07 hours. PAPM/BP was evaluated to be a less-epileptogenic carbapenem antibiotic.
Meguro
H
H
Department of Pediatrics, Ichihara Hospital, Teikyo University School of Medicine.
Mori
A
A
Fujii
R
R
Terashima
I
I
D001424:Bacterial Infections / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D004359:Drug Therapy, Combination / Q000097:blood / Q000627:therapeutic use; D005069:Evaluation Studies as Topic; D005260:Female; D006207:Half-Life; D006801:Humans; D007223:Infant; D008297:Male; D013845:Thienamycins / Q000097:blood / Q000627:therapeutic use*; D015091:beta-Alanine / Q000031:analogs & derivatives* / Q000097:blood / Q000627:therapeutic use
D013845:Thienamycins; D015091:beta-Alanine; C075316:panipenem-betamipron